It has also been reported that SMYD2 affects the resistance to platinum-based chemotherapy in patients with advanced-stage non-small cell lung cancer 20, and that SMYD2 inhibition enhances the efficacy of doxorubicin against ESCC in vitro21. Here, SMYD2 is linked to esophageal squamous cell carcinoma.